Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28668257 | 0.89 | PTGDR2 (0.49) | MEN1MAPTKMT2APTGDR2F10 | |
| SCHEMBL28688093 | 0.86 | PTGDR2 (0.54) | PTGDR2F10CYP2C9 | |
| SCHEMBL28672524 | 0.86 | PTGDR2 (0.65) | PTGDR2F10CYP2C9 | |
| SCHEMBL28676547 | 0.85 | HDAC6 (0.62) | — | |
| SCHEMBL28689658 | 0.85 | PTGDR2 (0.53) | PTGDR2F10CYP2C9 | |
| SCHEMBL28666341 | 0.81 | F10 (0.55) | F10 | |
| SCHEMBL28689645 | 0.81 | PTGDR2 (0.52) | PTGDR2F10CYP2C9 | |
| SCHEMBL28683412 | 0.81 | F10 (0.53) | PTGDR2F10CYP2C9 | |
| SCHEMBL28665679 | 0.80 | PTGDR2 (0.55) | PTGDR2F10CYP2C9 | |
| SCHEMBL28683406 | 0.79 | CYP2C9 (0.65) | PTGDR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113845522-A | Aminopeptidase N inhibitor and preparation method and application thereof | 山东省药学科学院 | 2021-12-28 | — | — | CN | claimed |
| CN-113845522-A | Aminopeptidase N inhibitor and preparation method and application thereof | 山东省药学科学院 | 2021-12-28 | — | — | CN | disclosed |